Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06372145




Registration number
NCT06372145
Ethics application status
Date submitted
15/04/2024
Date registered
17/04/2024

Titles & IDs
Public title
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Scientific title
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis
Secondary ID [1] 0 0
2023-503631-18
Secondary ID [2] 0 0
LTS17043
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis 0 0
Secondary Progressive Multiple Sclerosis 0 0
Progressive Relapsing Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tolebrutinib
Treatment: Drugs - Placebo
Treatment: Drugs - Teriflunomide

Experimental: Tolebrutinib - * Participants will receive OL tolebrunitib 60 mg once daily.
* RMS participants who are not eligible for OL tolebrutinib per Health Authority and/or ethics committee decisions on the study conduct (ie, partial hold on initiation of tolebrutinib) will continue their parent study treatment assignment as per their randomization from the parent study.

Active comparator: Teriflunomide - * participants will receive teriflunomide 14 mg daily
* RMS participants who are not eligible for OL tolebrutinib per Health Authority and/or ethics committee decisions on the study conduct (ie, partial hold on initiation of tolebrutinib) will continue their parent study treatment assignment (either tolebrutinib or teriflunomide) as per their randomization from the parent study. If unblinded to teriflunomide parent study treatment assignment, these RMS participants will continue teriflunomide in the LTS17043 study.


Treatment: Drugs: Tolebrutinib
Pharmaceutical form:Tablet-Route of administration:oral

Treatment: Drugs: Placebo
Pharmaceutical form:Tablet-Route of administration:oral

Treatment: Drugs: Teriflunomide
Pharmaceutical form:Tablet-Route of administration:oral
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuation
Timepoint [1] 0 0
From baseline until the End of study approximately 3 years per participant
Primary outcome [2] 0 0
Number of Participants with Potentially clinically significant abnormalities (PCSAs)
Timepoint [2] 0 0
From baseline until the End of study approximately 3 years per participant
Secondary outcome [1] 0 0
Time to onset of 6-month confirmed disability worsening (CDW for RMS) or confirmed disability progression (CDP for PPMS and NRSPMS) for participants from pivotal studies
Timepoint [1] 0 0
From baseline until the End of study approximately 3 years per participant
Secondary outcome [2] 0 0
Annualized Relapse Rate (ARR) for RMS only
Timepoint [2] 0 0
From baseline until the End of study approximately 3 years per participant
Secondary outcome [3] 0 0
Number of new and/or enlarging T2-hyperintense lesions per year
Timepoint [3] 0 0
From baseline until the End of study approximately 3 years per participant
Secondary outcome [4] 0 0
Change from baseline in total volume of T2-hyperintense lesions
Timepoint [4] 0 0
From baseline until the End of study approximately 3 years per participant
Secondary outcome [5] 0 0
ToleDYNAMIC substudy Change from baseline in biomarkers
Timepoint [5] 0 0
From baseline until 12 months per participant

Eligibility
Key inclusion criteria
- Participants with RMS, PPMS, or NRSPMS who completed the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 pivotal tolebrutinib trials (EFC16033, EFC16034, EFC16645, EFC16035) on IMP.

OR

- The Phase 2b LTS (LTS16004) or Phase 3 tolebrutinib pivotal trial participants who temporarily discontinued IMP due to a national emergency and completed the trial visits.

ToleDYNAMIC Substudy: Inclusion criteria are those of the main study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants are excluded from the study if any of the following criteria apply:
* The participant is at risk for or has a persistent chronic, active (including fever higher than 38°C and clinically unstable), or recurring systemic infection, as judged by the Investigator
* For participants initiating OL tolebrutinib in the LTS17043 study: Participants at risk of developing or having reactivation of hepatitis, ie, results at the unblinding visit (RMS) or opt-in visit (PMS) for serological markers for hepatitis B and C viruses indicating acute or chronic infection
* Active alcohol use disorder or a history of alcohol or drug abuse within 1 year prior to the opt-in visit
* Current alcohol intake equal to or exceeding the following at the opt-in visit: more than 2 drinks per day for men and more than 1 drink per day for women
* Abnormal ECG during the opt-in visit considered in the Investigator's judgment to be clinically significant, such as QTcF >500 msec, in the context of this study.
* A bleeding disorder, known platelet dysfunction, abnormal platelet count (<100,000/microliter), history of significant bleeding event or other conditions and planned procedures that may predispose the participant to excessive bleeding during the study, as judged by the Investigator.
* For participants initiating OL tolebrutinib in the LTS17043 study: Confirmed unblinding visit (RMS) or opt-in visit (PMS) alanine aminotransferase (ALT) more than 1.5 × upper limit of normal (ULN) OR aspartate aminotransferase (AST) more than 1.5 × ULN OR alkaline phosphatase more than 2 × ULN (unless caused by non-liver-related disorder or explained by a stable chronic liver disorder) OR total bilirubin more than 1.5 × ULN (unless due to Gilbert syndrome or non-liver-related disorder).
* Acute liver disease, cirrhosis, chronic liver disease (unless considered stable for more than 6 months).
* Participants who developed clinically relevant cardiovascular, hepatic, endocrine, neuropsychiatric or other major systemic disease making implementation of the protocol or interpretation of the trial results difficult or that would put the patient at risk by participating in the trial, as judged by the Investigator.
* The participant is receiving treatment during the study period with drugs not permitted by the study protocol, including potent and moderate inducers of cytochrome P450 (CYP) 3A or potent inhibitors of CYP2C8 hepatic enzymes.

NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

ToleDYNAMIC Substudy: Exclusion criteria are those of the main study

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/04/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/04/2029
Actual
Sample size
Target
2500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Investigational Site Number : 0360001 - Saint Leonards
Recruitment hospital [2] 0 0
Investigational Site Number : 0360006 - Kent Town
Recruitment hospital [3] 0 0
Investigational Site Number : 0360007 - Melbourne
Recruitment postcode(s) [1] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [2] 0 0
5067 - Kent Town
Recruitment postcode(s) [3] 0 0
3065 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Vermont
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad De Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Santa Fe
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Córdoba
Country [31] 0 0
Argentina
State/province [31] 0 0
San Miguel de Tucuman
Country [32] 0 0
Argentina
State/province [32] 0 0
San Miguel de Tucumán
Country [33] 0 0
Austria
State/province [33] 0 0
Innsbruck
Country [34] 0 0
Austria
State/province [34] 0 0
Linz
Country [35] 0 0
Austria
State/province [35] 0 0
Vienna
Country [36] 0 0
Belgium
State/province [36] 0 0
Bruges
Country [37] 0 0
Belgium
State/province [37] 0 0
Brussels
Country [38] 0 0
Belgium
State/province [38] 0 0
Gent
Country [39] 0 0
Belgium
State/province [39] 0 0
Leuven
Country [40] 0 0
Belgium
State/province [40] 0 0
Liège
Country [41] 0 0
Belgium
State/province [41] 0 0
Overpelt
Country [42] 0 0
Brazil
State/province [42] 0 0
Paraná
Country [43] 0 0
Brazil
State/province [43] 0 0
Rio Grande Do Sul
Country [44] 0 0
Brazil
State/province [44] 0 0
São Paulo
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Pleven
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Plovdiv
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Sofia
Country [48] 0 0
Canada
State/province [48] 0 0
Alberta
Country [49] 0 0
Canada
State/province [49] 0 0
British Columbia
Country [50] 0 0
Canada
State/province [50] 0 0
Ontario
Country [51] 0 0
Canada
State/province [51] 0 0
Quebec
Country [52] 0 0
Chile
State/province [52] 0 0
Reg Metropolitana De Santiago
Country [53] 0 0
Chile
State/province [53] 0 0
Santiago
Country [54] 0 0
China
State/province [54] 0 0
Beijing
Country [55] 0 0
China
State/province [55] 0 0
Changchun
Country [56] 0 0
China
State/province [56] 0 0
Changsha
Country [57] 0 0
China
State/province [57] 0 0
Chengdu
Country [58] 0 0
China
State/province [58] 0 0
Chongqing
Country [59] 0 0
China
State/province [59] 0 0
Fuzhou
Country [60] 0 0
China
State/province [60] 0 0
Guangzhou
Country [61] 0 0
China
State/province [61] 0 0
Hohhot
Country [62] 0 0
China
State/province [62] 0 0
Jiazhuang
Country [63] 0 0
China
State/province [63] 0 0
Nanjing
Country [64] 0 0
China
State/province [64] 0 0
Shanghai
Country [65] 0 0
China
State/province [65] 0 0
Shenyang
Country [66] 0 0
China
State/province [66] 0 0
Taiyuan
Country [67] 0 0
China
State/province [67] 0 0
Tianjin
Country [68] 0 0
China
State/province [68] 0 0
Wuhan
Country [69] 0 0
China
State/province [69] 0 0
Xi An
Country [70] 0 0
Croatia
State/province [70] 0 0
Zagreb
Country [71] 0 0
Czechia
State/province [71] 0 0
Brno
Country [72] 0 0
Czechia
State/province [72] 0 0
Hradec Kralove
Country [73] 0 0
Czechia
State/province [73] 0 0
Jihlava
Country [74] 0 0
Czechia
State/province [74] 0 0
Ostrava
Country [75] 0 0
Czechia
State/province [75] 0 0
Pardubice
Country [76] 0 0
Czechia
State/province [76] 0 0
Prague
Country [77] 0 0
Czechia
State/province [77] 0 0
Teplice
Country [78] 0 0
Czechia
State/province [78] 0 0
Zlín
Country [79] 0 0
Denmark
State/province [79] 0 0
Esbjerg
Country [80] 0 0
Denmark
State/province [80] 0 0
Holstebro
Country [81] 0 0
Denmark
State/province [81] 0 0
Odense
Country [82] 0 0
Estonia
State/province [82] 0 0
Tallinn
Country [83] 0 0
Finland
State/province [83] 0 0
Tampere
Country [84] 0 0
Finland
State/province [84] 0 0
Turku
Country [85] 0 0
France
State/province [85] 0 0
Besançon
Country [86] 0 0
France
State/province [86] 0 0
Bron
Country [87] 0 0
France
State/province [87] 0 0
Clermont-ferrand
Country [88] 0 0
France
State/province [88] 0 0
Gonesse
Country [89] 0 0
France
State/province [89] 0 0
Lille
Country [90] 0 0
France
State/province [90] 0 0
Montpellier
Country [91] 0 0
France
State/province [91] 0 0
Nancy
Country [92] 0 0
France
State/province [92] 0 0
Nice
Country [93] 0 0
France
State/province [93] 0 0
Nîmes
Country [94] 0 0
France
State/province [94] 0 0
Paris
Country [95] 0 0
France
State/province [95] 0 0
Poissy
Country [96] 0 0
France
State/province [96] 0 0
Rennes
Country [97] 0 0
France
State/province [97] 0 0
Saint-herblain
Country [98] 0 0
France
State/province [98] 0 0
Strasbourg
Country [99] 0 0
France
State/province [99] 0 0
Toulouse
Country [100] 0 0
Germany
State/province [100] 0 0
Bayreuth
Country [101] 0 0
Germany
State/province [101] 0 0
Berlin
Country [102] 0 0
Germany
State/province [102] 0 0
Bochum
Country [103] 0 0
Germany
State/province [103] 0 0
Dresden
Country [104] 0 0
Germany
State/province [104] 0 0
Düsseldorf
Country [105] 0 0
Germany
State/province [105] 0 0
Essen
Country [106] 0 0
Germany
State/province [106] 0 0
Giessen
Country [107] 0 0
Germany
State/province [107] 0 0
Hamburg
Country [108] 0 0
Germany
State/province [108] 0 0
Münster
Country [109] 0 0
Germany
State/province [109] 0 0
ULM
Country [110] 0 0
Germany
State/province [110] 0 0
Wã¼rzburg
Country [111] 0 0
Greece
State/province [111] 0 0
Athens
Country [112] 0 0
Greece
State/province [112] 0 0
Larissa
Country [113] 0 0
Greece
State/province [113] 0 0
Thessaloniki
Country [114] 0 0
Hong Kong
State/province [114] 0 0
Sha Tin
Country [115] 0 0
Hungary
State/province [115] 0 0
Budapest
Country [116] 0 0
Hungary
State/province [116] 0 0
Pã©cs
Country [117] 0 0
India
State/province [117] 0 0
Chandigarh
Country [118] 0 0
India
State/province [118] 0 0
Gurugram
Country [119] 0 0
India
State/province [119] 0 0
Mangaluru
Country [120] 0 0
India
State/province [120] 0 0
Nagpur
Country [121] 0 0
India
State/province [121] 0 0
New Delhi
Country [122] 0 0
India
State/province [122] 0 0
Thiruvananthapuram
Country [123] 0 0
Israel
State/province [123] 0 0
Haifa
Country [124] 0 0
Israel
State/province [124] 0 0
Ramat Gan
Country [125] 0 0
Israel
State/province [125] 0 0
Rehovot
Country [126] 0 0
Israel
State/province [126] 0 0
Safed
Country [127] 0 0
Italy
State/province [127] 0 0
Firenze
Country [128] 0 0
Italy
State/province [128] 0 0
Lombardia
Country [129] 0 0
Italy
State/province [129] 0 0
Roma
Country [130] 0 0
Italy
State/province [130] 0 0
Toscana
Country [131] 0 0
Italy
State/province [131] 0 0
Bergamo
Country [132] 0 0
Italy
State/province [132] 0 0
Cagliari
Country [133] 0 0
Italy
State/province [133] 0 0
Catania
Country [134] 0 0
Italy
State/province [134] 0 0
Genoa
Country [135] 0 0
Italy
State/province [135] 0 0
Milan
Country [136] 0 0
Italy
State/province [136] 0 0
Naples
Country [137] 0 0
Italy
State/province [137] 0 0
Pavia
Country [138] 0 0
Italy
State/province [138] 0 0
Pozzilli
Country [139] 0 0
Italy
State/province [139] 0 0
Rome
Country [140] 0 0
Japan
State/province [140] 0 0
Iwate
Country [141] 0 0
Japan
State/province [141] 0 0
Kanagawa
Country [142] 0 0
Japan
State/province [142] 0 0
Saitama
Country [143] 0 0
Japan
State/province [143] 0 0
Kyoto
Country [144] 0 0
Japan
State/province [144] 0 0
Osaka
Country [145] 0 0
Japan
State/province [145] 0 0
Tokyo
Country [146] 0 0
Korea, Republic of
State/province [146] 0 0
Gyeonggi-do
Country [147] 0 0
Korea, Republic of
State/province [147] 0 0
Seoul-teukbyeolsi
Country [148] 0 0
Latvia
State/province [148] 0 0
Riga
Country [149] 0 0
Lithuania
State/province [149] 0 0
Kaunas
Country [150] 0 0
Lithuania
State/province [150] 0 0
Siauliai
Country [151] 0 0
Lithuania
State/province [151] 0 0
Vilnius
Country [152] 0 0
Mexico
State/province [152] 0 0
Ciudad De Mexico
Country [153] 0 0
Mexico
State/province [153] 0 0
Veracruz
Country [154] 0 0
Netherlands
State/province [154] 0 0
Amsterdam
Country [155] 0 0
Netherlands
State/province [155] 0 0
Heerlen
Country [156] 0 0
Norway
State/province [156] 0 0
Bergen
Country [157] 0 0
Norway
State/province [157] 0 0
Oslo
Country [158] 0 0
Poland
State/province [158] 0 0
Kujawsko-pomorskie
Country [159] 0 0
Poland
State/province [159] 0 0
Lódzkie
Country [160] 0 0
Poland
State/province [160] 0 0
Mazowieckie
Country [161] 0 0
Poland
State/province [161] 0 0
Podkarpackie
Country [162] 0 0
Poland
State/province [162] 0 0
Slaskie
Country [163] 0 0
Poland
State/province [163] 0 0
Wielkopolskie
Country [164] 0 0
Poland
State/province [164] 0 0
Katowice
Country [165] 0 0
Poland
State/province [165] 0 0
Lublin
Country [166] 0 0
Poland
State/province [166] 0 0
Zabrze
Country [167] 0 0
Portugal
State/province [167] 0 0
Braga
Country [168] 0 0
Portugal
State/province [168] 0 0
Coimbra
Country [169] 0 0
Portugal
State/province [169] 0 0
Lisbon
Country [170] 0 0
Portugal
State/province [170] 0 0
Santa Maria Da Feira
Country [171] 0 0
Puerto Rico
State/province [171] 0 0
Guaynabo
Country [172] 0 0
Romania
State/province [172] 0 0
Bra?ov
Country [173] 0 0
Romania
State/province [173] 0 0
Bucharest
Country [174] 0 0
Romania
State/province [174] 0 0
Cluj-napoca
Country [175] 0 0
Romania
State/province [175] 0 0
Constanta
Country [176] 0 0
Romania
State/province [176] 0 0
Câmpulung
Country [177] 0 0
Romania
State/province [177] 0 0
Oradea
Country [178] 0 0
Romania
State/province [178] 0 0
Sibiu
Country [179] 0 0
Romania
State/province [179] 0 0
Timisoara
Country [180] 0 0
Serbia
State/province [180] 0 0
Belgrade
Country [181] 0 0
Serbia
State/province [181] 0 0
Kragujevac
Country [182] 0 0
Serbia
State/province [182] 0 0
Novi Sad
Country [183] 0 0
Slovakia
State/province [183] 0 0
Bratislava
Country [184] 0 0
Slovakia
State/province [184] 0 0
Martin
Country [185] 0 0
Slovakia
State/province [185] 0 0
Nitra
Country [186] 0 0
Spain
State/province [186] 0 0
A Coruña [La Coruña]
Country [187] 0 0
Spain
State/province [187] 0 0
Andalucia
Country [188] 0 0
Spain
State/province [188] 0 0
Barcelona [Barcelona]
Country [189] 0 0
Spain
State/province [189] 0 0
Bizkaia
Country [190] 0 0
Spain
State/province [190] 0 0
Gipuzkoa
Country [191] 0 0
Spain
State/province [191] 0 0
Girona [Gerona]
Country [192] 0 0
Spain
State/province [192] 0 0
Las Palmas
Country [193] 0 0
Spain
State/province [193] 0 0
Lleida [Lérida]
Country [194] 0 0
Spain
State/province [194] 0 0
Madrid, Comunidad De
Country [195] 0 0
Spain
State/province [195] 0 0
Madrid
Country [196] 0 0
Spain
State/province [196] 0 0
Córdoba
Country [197] 0 0
Spain
State/province [197] 0 0
Murcia
Country [198] 0 0
Spain
State/province [198] 0 0
Málaga
Country [199] 0 0
Spain
State/province [199] 0 0
Valencia
Country [200] 0 0
Sweden
State/province [200] 0 0
Gothenburg
Country [201] 0 0
Sweden
State/province [201] 0 0
Stockholm
Country [202] 0 0
Switzerland
State/province [202] 0 0
Bern
Country [203] 0 0
Taiwan
State/province [203] 0 0
Hsinchu
Country [204] 0 0
Taiwan
State/province [204] 0 0
Taipei City
Country [205] 0 0
Turkey
State/province [205] 0 0
Akdeniz
Country [206] 0 0
Turkey
State/province [206] 0 0
Ankara
Country [207] 0 0
Turkey
State/province [207] 0 0
Eskisehir
Country [208] 0 0
Turkey
State/province [208] 0 0
Istanbul
Country [209] 0 0
Turkey
State/province [209] 0 0
Izmir
Country [210] 0 0
Turkey
State/province [210] 0 0
Izmit
Country [211] 0 0
Turkey
State/province [211] 0 0
Kütahya
Country [212] 0 0
Turkey
State/province [212] 0 0
Samsun
Country [213] 0 0
Ukraine
State/province [213] 0 0
Chernivtsi
Country [214] 0 0
Ukraine
State/province [214] 0 0
Dnipro
Country [215] 0 0
Ukraine
State/province [215] 0 0
Ivano-Frankivsk
Country [216] 0 0
Ukraine
State/province [216] 0 0
Kharkiv
Country [217] 0 0
Ukraine
State/province [217] 0 0
Kyiv
Country [218] 0 0
Ukraine
State/province [218] 0 0
Lutsk
Country [219] 0 0
Ukraine
State/province [219] 0 0
Lviv
Country [220] 0 0
Ukraine
State/province [220] 0 0
Odesa
Country [221] 0 0
Ukraine
State/province [221] 0 0
Vinnytsia
Country [222] 0 0
United Kingdom
State/province [222] 0 0
Devon
Country [223] 0 0
United Kingdom
State/province [223] 0 0
Kent
Country [224] 0 0
United Kingdom
State/province [224] 0 0
London, City Of
Country [225] 0 0
United Kingdom
State/province [225] 0 0
Manchester
Country [226] 0 0
United Kingdom
State/province [226] 0 0
Oxfordshire
Country [227] 0 0
United Kingdom
State/province [227] 0 0
Bristol
Country [228] 0 0
United Kingdom
State/province [228] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Trial Transparency email recommended (Toll free for US & Canada)
Address 0 0
Country 0 0
Phone 0 0
800-633-1610
Fax 0 0
Email 0 0
Contact-US@sanofi.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06372145